文献速递新生儿儿童呼吸

26-28周早产儿动脉导管未闭管理变化与结局

Changes in Patent Ductus Arteriosus Management and Outcomes in Infants Born at 26-28 Weeks' Gestation.
PubMed 文献 · J Pediatr · 2024-12-26

该回顾性队列纳入2012-2021年NICHD新生儿研究网络中持续参与医院的7864例26 0/7-28 6/7周早产儿,发现任何PDA治疗从21%降至16%(P<.01),主要复合结局从24%升至36%(P<.01),主要由2-3级BPD增加驱动(13%-26%,P<.01),其中2级BPD增幅最大(10%-22%,P<.01)。校正患者因素后PDA治疗减少与主要结局及2-3级BPD增加相关(P<.01),但分层分析显示无论PDA管理变化如何,所有医院组2-3级BPD均增加,因果关系需谨慎。

要点

  • 2012-2021年26-28周早产儿PDA治疗率从21%降至16%,主要复合结局从24%升至36%。
  • 主要结局增加主要由2-3级BPD增加驱动(13%-26%),其中2级BPD增幅最大(10%-22%)。
  • 分层分析显示所有医院组2-3级BPD均增加,与PDA管理变化无关,因果关系需谨慎。

核心结论

  • 2012至2021年间,26-28周早产儿PDA治疗减少与2-3级BPD增加相关,但需谨慎判断因果关系。
  • 过去十年2-3级BPD增加的原因值得进一步研究。

研究设计与样本

  • 回顾性队列研究,纳入2012-2021年NICHD新生儿研究网络中持续参与医院的7864例26 0/7-28 6/7周早产儿。
  • 主要复合结局定义为外科坏死性小肠结肠炎、2-3级支气管肺发育不良(BPD)、严重脑室内出血或死亡。
  • 采用多层模型校正患者层面因素分析PDA治疗时间趋势与主要复合结局及其组分的关系,并按医院PDA治疗变化进行分层分析。

主要发现

  • 任何PDA治疗从21%降至16%(P<.01),主要复合结局从24%升至36%(P<.01)。
  • 主要结局变化由2-3级BPD增加驱动(13%-26%,P<.01),其中2级BPD占大部分增幅(10%-22%,P<.01)。
  • 校正患者因素后,PDA治疗的时间性减少与主要结局及2-3级BPD增加相关(P<.01)。
  • 分层分析显示,无论PDA管理变化如何,所有医院组2-3级BPD均增加。

临床怎么用

  • 临床需关注26-28周早产儿PDA治疗减少背景下2-3级BPD的增加趋势。
  • 不应仅依据本研究推断PDA治疗减少与BPD增加的因果关系,需结合个体情况决策。

局限性

  • 为回顾性队列研究,作者提示判断因果关系需谨慎。
  • 分层分析显示所有医院组2-3级BPD均增加,与PDA管理变化无关,提示可能存在其他未测量因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the association between the secular decrease in treatment of patent ductus arteriosus (PDA) and trends in neonatal mortality and morbidity in infants born at 26 0/7-28 6/7 weeks' gestation. STUDY DESIGN: A retrospective cohort study including infants born between 2012 and 2021 in continually participating hospitals in the National Institute of Child Health and Human Development Neonatal Research Network. The primary composite outcome was defined as surgical necrotizing enterocolitis, grade 2-3 bronchopulmonary dysplasia (BPD), severe intraventricular hemorrhage, or death. Relationships of temporal trends in PDA treatment with the primary composite outcome and its components were analyzed using a multilevel model accounting for patient-level factors. A separate analysis assessed these relationships stratified by hospital changes in PDA treatment. RESULTS: The study included 7864 infants. There was a decrease in any PDA treatment from 21% to 16% (P < .01) and an increase in the primary composite outcome from 24% to 36% (P < .01). Change in the primary outcome was driven by increased grade 2-3 BPD (13%-26%, P < .01), with grade 2 BPD accounting for most of this increase (10%-22%, P < .01). Temporal decreases in PDA treatment were associated with increases in the primary outcome and grade 2-3 BPD after adjusting for patient-level factors (P < .01). However, stratified analyses showed that grade 2-3 BPD increased in all hospital groups, regardless of changes in PDA management. CONCLUSIONS: From 2012 to 2021, temporal decreases in PDA treatment for infants 26-28 weeks were associated with an increase in grade 2-3 BPD. However, caution is warranted in determining causality. Reasons for increased grade 2-3 BPD during the past decade warrant investigation. TRIAL REGISTRATION: Generic Database: NCT00063063.

来源:J Pediatr,查看原文。版权归原作者所有。

引用

  1. Kaluarachchi DC, Rysavy MA, Do BT, et al. Changes in Patent Ductus Arteriosus Management and Outcomes in Infants Born at 26-28 Weeks' Gestation. J Pediatr. 2024. PMID: 39732160. doi:10.1016/j.jpeds.2024.114456

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。